<DOC>
	<DOCNO>NCT01665014</DOCNO>
	<brief_summary>The purpose study evaluate use total marrow irradiation ( TMI ) sole preparation first autologous hematopoietic stem cell transplantation ( autoHSCT ) follow high-dose melphalan use prior second autoHSCT safe effective patient multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Total Marrow Irradiation High-dose Melphalan Double Autologous Hematopoietic Stem Cell Transplantation Multiple Myeloma</brief_title>
	<detailed_description>AutoHSCT standard treatment patient MM . According soem clinical evidence double autoHSCT provide survival advantage compare single procedure . Most frequently use condition regimen consist pf high dos melphalan ( HD-MEL ) . In study use combination total body irradiation ( TBI ) , , however associate significant toxicity . In center standard procedure include TBI single treatment 1st autoHSCT HD-Mel 2nd autoHSCT . As MM malignant plasma cell localize almost exclusively bone marrow rationale limit irradiation bone . For purpose current study substitute TBI TMI . Additional boost provide active site disease base PET/CT image . Our intention minimize toxicity maintain treatment efficacy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Age 1865 year Diagnosis multiple myeloma PR , VGPR CR inclusion Performance status WHO 01 Written inform consent Organ dysfunction : elevated ALT , AST , bilirubin , AF ; creatinine &gt; 1.5 upper normal limit ; LVEF &lt; 45 % Active infection Unstable diabetes Psychiatric disease History highdose chemotherapy irradiation Second malignancy Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>autologous hematopoietic stem cell transplantation</keyword>
	<keyword>total marrow irradiation</keyword>
	<keyword>melphalan</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>